{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-120188","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.176551+00:00","generated_at":"2026-05-30T06:08:42.210580+00:00","sec_items":["1.01","3.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Aptevo Therapeutics extends poison pill expiration to Oct 2025, adjusts purchase price to $70","bullets":["Amendment No. 4 extends Rights Agreement Final Expiration Date to October 31, 2025.","Purchase Price changed to $70 per one one-thousandth of a Series A Preferred Share.","Rights Agreement originally dated November 8, 2020; Amendment modified rights of security holders.","Entered into with Broadridge Corporate Issuer Solutions as Rights Agent."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-120188","json":"https://secwatch.observer/filing/0000950170-24-120188.json","markdown":"https://secwatch.observer/filing/0000950170-24-120188.md","text":"https://secwatch.observer/filing/0000950170-24-120188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024120188/0000950170-24-120188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024120188/apvo-20241101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:08:42.210580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}